A phase 1a/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumors

Falchook, G. S., Peeters, M., Rottey, S., Dirix, L. Y., Obermannova, R., Cohen, J. E., Perets, R., Frommer, R. S., Bauer, T. M., Wang, J. S., Carvajal, R. D., Sabari, J., Chapman, S., Zhang, W., Calderon, B., & Peterson, D. A. (2021). A phase 1a/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumors. Investigational New Drugs, 39(5), 1284–1297. https://doi.org/10.1007/s10637-021-01088-4
Authors:
Gerald S. Falchook
Marc Peeters
Sylvie Rottey
Luc Y. Dirix
Radka Obermannova
Jonathan E. Cohen
Ruth Perets
Ronnie Shapira Frommer
Todd M. Bauer
Judy S. Wang
Richard D. Carvajal
Joshua Sabari
Sonya Chapman
Wei Zhang
Boris Calderon
Daniel A. Peterson
Affiliated Authors:
Richard D. Carvajal
Columbia Affiliation:
Author Keywords:
advanced solid cancer
csf-1
csf-1r inhibitor
ly3022855
nsclc
ovarian cancer
elink
Publication Type:
Article
Unique ID:
10.1007/s10637-021-01088-4
PMID:
33852104
DOI:
10.1007/s10637-021-01088-4
Journal:
Investigational New Drugs
Publication Date:
Data Source:
Scopus
Source Link:
View Scopus Record

Record Created: